Only one in four Black patients with advanced or metastatic non-small cell lung cancer underwent next-generation sequencing before first-line therapy compared with one in three white patients, according to results of a retrospective study.The findings, presented during the virtual ASCO Annual Meeting, reflect the need to improve access to comprehensive genomic testing during the front-line